Scientific Results

OUR LEAD MOLECULE PN6047 has the ability to become a medicine for the treatment of chronic pain. This is underpinned by the following:

  • PN6047 is a novel US patented molecule without any toxic effects in preclinical testing. PN6047 can be cost effectively synthesized
  • PN6047 is highly selective for the delta opioid receptor and does not interact with other receptors, transporters or enzymes
  • PN6047 preferentially signals via Gi proteins compared with arrestin proteins
  • PN6047 has high potency and efficacy in reducing chronic pain in various animal models
  • PN6047 lacks unwanted morphine-like side-effects, such as analgesic tolerance, drug abuse potential and respiratory depression
  • PN6047 has an excellent preclinical safety profile lacking CVS/GIT interactions and seizure induction
  • PN6047 shows no histopathological  effects following long-term multiple high dose administration.

THUS, PN6047 can be the drug of choice to combat chronic pain and other conditions involving sensory hypersensitivity such as chronic cough and itch.

Pn6047 vs. conventional
Read more →

The advantages with PN6047, our selective, biased DOR agonist, versus traditional medicines in treating cronic pain are potentially substantial.

vs Conventional Opioids:  
Better efficacy in sensory hypersensitivity disorders; no μ-receptor side effects; no analgesic  tolerance; no abuse potential.

vs Gabapentin:
Lower dose; no dose adjustment in renal insufficiency patients; no abuse potential; no cytochrome enzyme inhibition so less drug interactions.

vs Amitriptyline:
Lower dose; no cardiovascular complications; lower metabolite exposure; no dose adjustment in hepatic insufficiency patients; no significant food or drug interactions.

Find us

PharmNovo AB
Medicon Village AB
Scheelevägen 6
SE-223 81 Lund, Sweden

Map